Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $96.57 which represents a decrease of $-1.33 or -1.36% from the prior close of $97.9. The stock opened at $96.05 and ...

Presentation Operator Good afternoon, everyone, and welcome to Gilead's Third Quarter 2024 Earnings Conference Call. My name ...

Piper Sandler raised the firm’s price target on Gilead (GILD) to $105 from $95 and keeps an Overweight rating on the shares. The firm ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial results that handily beat Wall ...

Baird raised the firm’s price target on Gilead (GILD) to $95 from $80 and keeps a Neutral rating on the shares. The firm said its was ...

Q3 2024 Earnings Call Nov 06, 2024, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants.

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

2024 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) announced today that Paul Petrelli joined the organization as Vice ...

In his new role, Petrelli will be responsible for leading the commercial organization for Gilead Canada, with a focus on ...

Gilead Sciences, Inc. (NASDAQ:GILD ... The speakers on today's call will be our Chairman and Chief Executive Officer, Daniel O'Day; our Chief Commercial Officer, Johanna Mercier; our Chief Medical ...